- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Goldman Sachs Boosts Syndax Pharmaceuticals Stock Price Target
Analysts see potential 44% upside for the biotech company's shares
Apr. 1, 2026 at 6:21pm
Got story updates? Submit your updates here. ›
Analysts at The Goldman Sachs Group have increased their target price on shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from $28.00 to $34.00 and maintained a "buy" rating on the stock. The new price target suggests a potential upside of 44.62% from the stock's current trading price.
Why it matters
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The positive outlook from a major investment bank like Goldman Sachs could signal growing confidence in the company's drug pipeline and future prospects.
The details
In a research note, Goldman Sachs analysts cited Syndax's lead investigational candidate, entinostat, as a key driver behind the increased price target. Entinostat is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. The analysts believe entinostat has the potential to enhance the effectiveness of existing cancer treatments and address high unmet medical needs.
- The Goldman Sachs research note was issued on Wednesday, April 1, 2026.
The players
The Goldman Sachs Group
A multinational investment bank and financial services company.
Syndax Pharmaceuticals
A clinical-stage biopharmaceutical company focused on developing novel cancer therapies.
Entinostat
Syndax's lead investigational candidate, a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.
The takeaway
The increased price target from Goldman Sachs suggests growing optimism around Syndax Pharmaceuticals' drug pipeline, particularly its lead candidate entinostat. This could signal a positive outlook for the company's future performance and potential to address unmet needs in the cancer treatment landscape.
